Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 767-769, 2004; 10.1373/clinchem.2003.027797
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dighe, A. S.
Right arrow Articles by Sluss, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dighe, A. S.
Right arrow Articles by Sluss, P. M.
Related Collections
Right arrow Laboratory Management
Right arrow General Clinical Chemistry
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2004;50:767-769.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

Comparison of Inhibin A Immunoassays: Recommendation for Adoption of Standardized Reporting

Anand S. Dighe1, Frances J. Hayes1, Javad Khosravi2,4, Umesh Bodani3 and Patrick M. Sluss1,a

1 Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114;2 Diagnostic System Laboratories (Canada) Inc., Toronto, Ontario, Canada;3 Diagnostics Systems Laboratories Inc., Webster, TX;4 Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada

aauthor for correspondence: fax 617-726-9330, e-mail psluss@partners.org

The first 300 words of the full text of this article appear below.

Serum inhibin A measurements have become increasingly common in clinical use, and their inclusion in prenatal screening for Down syndrome has been recently advocated. Two methods are commercially available for the specific measurement of dimeric inhibin A in human serum or plasma (1). Given the absence of a gold standard and the evolving clinical utility of inhibin A, a detailed comparison of the two inhibin A ELISAs is warranted. In the studies reported here, we undertook the evaluation of these methods and a direct comparison of their performance. The results obtained support the use of both methods and provide a basis for comparing values across these methods. Furthermore, we recommend that laboratories adopt a reporting unit of IU/mL based on the recombinant human Inhibin A International Reference Preparation (IRP) distributed by the National Institute for Biological Standards and Control on behalf of the WHO (91/624).

Inhibin A is a dimeric glycoprotein hormone belonging to the transforming growth factor-ß superfamily of cytokines. In addition to its numerous local, tissue-specific regulatory or "cytokine-type" actions (2)(3)(4), ovary-produced inhibin A is an important negative feedback hormone that suppresses pituitary secretion of follicle-stimulating hormone during the late follicular and luteal phases of the menstrual cycle (5)(6). Furthermore, circulating concentrations of inhibin A appear to reflect tumor mass for certain forms of ovarian cancer (7), particularly granulosa cell adenocarcinomas, and measurement of inhibin A also may be useful in assessment of gestational trophoblastic disease (8)(9). In addition, the measurement of serum inhibin A has recently been demonstrated as useful in the clinical setting as part of the "quadruple" antenatal screen for Down syndrome (10)(11)(12).

The only analytical methods developed to date for . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.